Should I buy or sell Arvinas stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks .

What is Arvinas' stock price target for 2024?

16 brokers have issued 12 month price objectives for Arvinas' shares. Their ARVN share price targets range from $20.00 to $90.00. On average, they anticipate the company's stock price to reach $59.73 in the next year. This suggests a possible upside of 74.2% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts .

How have ARVN shares performed in 2024?

Arvinas' stock was trading at $41.16 on January 1st, 2024. Since then, ARVN stock has decreased by 16.7% and is now trading at $34.29. View the best growth stocks for 2024 here .

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the days-to-cover ratio is presently 11.7 days. View Arvinas' Short Interest .

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ARVN earnings forecast .

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Tuesday, February, 27th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by $1.38. The business earned ($43.10) million during the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. During the same period in the prior year, the firm earned ($1.56) EPS.

What ETFs hold Arvinas' stock?

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO) . iShares U.S. Pharmaceuticals ETF (IHE) .

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX) , ImmunoGen (IMGN) , Pfizer (PFE) , CRISPR Therapeutics (CRSP) , Energy Transfer (ET) , OPKO Health (OPK) , Advanced Micro Devices (AMD) , Enphase Energy (ENPH) , Fortress Biotech (FBIO) and Gilead Sciences (GILD) .

When did Arvinas IPO?

Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Bradley Albert Margus , Briggs Morrison , Ian Taylor , John G Houston, John G Houston , Liam Ratcliffe , Ronald Peck , Sean A Cassidy and Timothy M Shannon . View institutional ownership trends .

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:ARVN

Arvinas (ARVN) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free ARVN Stock Alerts

$34.29

+0.84 (+2.51%)

(As of 04/18/2024 ET)

Compare

Today's Range: $32.61
▼
$34.46
50-Day Range: $33.44
▼
$52.31
52-Week Range: $13.57
▼
$53.08

Volume: 803,076 shs
Average Volume: 722,184 shs
Market Capitalization: $2.33 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $59.73

Get Arvinas alerts:

Arvinas MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 74.2% Upside
$59.73 Price Target
Short Interest: Bearish
12.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.58
Based on 7 Articles This Week
Insider Trading: Selling Shares
$404,489 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.02) to ($4.95) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.33 out of 5 stars

Medical Sector

503rd out of 919 stocks

Pharmaceutical Preparations Industry

217th out of 405 stocks

4.4

Analyst's Opinion

Consensus Rating
Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Arvinas has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
12.63% of the outstanding shares of Arvinas have been sold short.
Short Interest Ratio / Days to Cover
Arvinas has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Arvinas has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Arvinas does not currently pay a dividend.
Dividend Growth
Arvinas does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARVN.

2.0

News and Social Media Coverage

News Sentiment
Arvinas has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Arvinas this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $404,489.00 in company stock.
Percentage Held by Insiders
Only 2.55% of the stock of Arvinas is held by insiders.
Percentage Held by Institutions
95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arvinas are expected to grow in the coming year, from ($5.02) to ($4.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arvinas is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arvinas is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arvinas has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad The Bull Report

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic

About Arvinas Stock (NASDAQ:ARVN)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ARVN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARVN Stock News Headlines

April 17, 2024 | americanbankingnews.com

Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 8.6% in March

April 14, 2024 | americanbankingnews.com

Arvinas (NASDAQ:ARVN) Price Target Lowered to $87.00 at HC Wainwright

April 18, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

April 13, 2024 | americanbankingnews.com

Arvinas (NASDAQ:ARVN) Shares Gap Up to $36.73

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential

April 11, 2024 | investors.com

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

April 11, 2024 | markets.businessinsider.com

Arvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock Jumps

April 11, 2024 | globenewswire.com

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

March 20, 2024 | seekingalpha.com

Arvinas gets new chief medical officer

March 19, 2024 | msn.com

Arvinas gets new chief medical head

March 18, 2024 | globenewswire.com

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

March 4, 2024 | globenewswire.com

Arvinas to Participate in Upcoming Investor Conferences

March 3, 2024 | seekingalpha.com

Arvinas: Behind The Huge Rally

March 1, 2024 | finance.yahoo.com

Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

February 28, 2024 | markets.businessinsider.com

Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease Treatment

February 28, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)

February 28, 2024 | markets.businessinsider.com

Navigating 7 Analyst Ratings For Arvinas

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial Health

February 27, 2024 | benzinga.com

Arvinas: Q4 Earnings Insights

February 27, 2024 | globenewswire.com

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

February 24, 2024 | finance.yahoo.com

Arvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past week

February 22, 2024 | marketwatch.com

Arvinas CFO Cassidy to Depart, Teel to Take Over on Interim Basis

February 21, 2024 | finance.yahoo.com

What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?

February 21, 2024 | finanznachrichten.de

Arvinas Inc.: Arvinas Announces Chief Financial Officer Transition

February 20, 2024 | msn.com

Arvinas announces CFO Sean Cassidy's departure

February 20, 2024 | finance.yahoo.com

Arvinas Announces Chief Financial Officer Transition

See More Headlines

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/03/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARVN
CUSIP: N/A
CIK: 1655759
Web: www.arvinas.com
Phone: (203) 535-1456
Fax: N/A
Employees: 445
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $59.73
High Stock Price Target: $90.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +74.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-367,300,000.00
Net Margins: -185.09%
Pretax Margin: -463.57%
Return on Equity: -70.24%
Return on Assets: -31.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.98
Quick Ratio: 4.98

Sales & Book Value

Annual Sales: $78.50 million
Price / Sales: 29.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.99 per share
Price / Book: 2.86

Miscellaneous

Outstanding Shares: 68,080,000
Free Float: 66,348,000
Market Cap: $2.33 billion
Optionable: Optionable
Beta: 1.94

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. John G. Houston Ph.D. (Age 64)
Chairperson, CEO & President
Comp: $1.08M
Dr. Ian Taylor Ph.D. (Age 61)
Chief Scientific Officer
Comp: $692k
Dr. Randy Teel Ph.D. (Age 44)
Interim CFO & Treasurer
Mr. David K. Loomis M.B.A. (Age 50)
VP, Principal Accounting Officer & Chief Accounting Officer
Mr. Jeff Boyle
Vice President of Investor Relations
Mr. Jared M. Freedberg J.D. (Age 55)
General Counsel & Corporate Secretary
Mr. Steve Weiss (Age 54)
Senior VP & Chief Human Resources Officer
Dr. John A. Grosso Ph.D. (Age 67)
Senior Vice President of R&D Technical Operations
Ms. Angela M. Cacace Ph.D. (Age 56)
Senior Vice President of Neuroscience & Platform Biology
Mr. John P. Northcott (Age 46)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.
What is Arvinas' stock price target for 2024?: 16 brokers have issued 12 month price objectives for Arvinas' shares. Their ARVN share price targets range from $20.00 to $90.00. On average, they anticipate the company's stock price to reach $59.73 in the next year. This suggests a possible upside of 74.2% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.
How have ARVN shares performed in 2024?: Arvinas' stock was trading at $41.16 on January 1st, 2024. Since then, ARVN stock has decreased by 16.7% and is now trading at $34.29.
View the best growth stocks for 2024 here.
Are investors shorting Arvinas?: Arvinas saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average daily volume of 735,200 shares, the days-to-cover ratio is presently 11.7 days.
View Arvinas' Short Interest.
When is Arvinas' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ARVN earnings forecast.
How were Arvinas' earnings last quarter?: Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Tuesday, February, 27th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by $1.38. The business earned ($43.10) million during the quarter, compared to analyst estimates of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. During the same period in the prior year, the firm earned ($1.56) EPS.

What ETFs hold Arvinas' stock?: ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO).iShares U.S. Pharmaceuticals ETF (IHE).
What other stocks do shareholders of Arvinas own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).
When did Arvinas IPO?: Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.
Who are Arvinas' major shareholders?: Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends.
How do I buy shares of Arvinas?: Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARVN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arvinas (ARVN) Stock Price, News & Analysis

Arvinas MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Arvinas Stock (NASDAQ:ARVN)

ARVN Stock Price History

ARVN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ARVN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™